EOD Primary Tumor

Notes

**Note 1:** When both the Federation Internationale de Gynecologie et d'Obstetrique (FIGO) stage and extension information on the primary tumor are available, use the extension information to code primary tumor in preference to a statement of FIGO stage. **Note 2:** EOD Primary Tumor includes direct extension or discontinuous metastasis to the vagina (see codes 400 and 550). **Note 3:** EOD Primary tumor excludes metastasis to adnexa or uterine serosa (See EOD Mets).
Code Description SS2018 T
100 Localized, NOS Confined to cervix uteri or uterus, NOS, except corpus uteri, NOS FIGO Stage IA, IB, I [NOS] Peritoneal Cytology with Primary Tumor for SS2018 T
200 Corpus uteri, NOS Confined to corpus uteri, size, depth and horizontal spread unknown RE
300 Extension of metastasis within true pelvis * Fallopian tube(s) * Ligaments (broad, round, uterosacral) * Ovary(ies) * Parametrium * Visceral peritoneum of pelvic organs FIGO Stage IIA RE
400 Cul de sac (rectouterine pouch) Parietal serosa of pelvic cavity Pelvic wall(s) Ureter, intra- and extramural Vagina, NOS Vaginal wall, NOS Vulva Described clinically as "frozen pelvis," NOS FIGO Stage IIB RE
500 Invasion beyond uterus, NOS FIGO Stage II [NOS] RE
550 Infiltration of abdominal tissues, one of the following sites * Bladder wall * Bladder, NOS excluding mucosa * Hydronephrosis or nonfunctioning kidney * Pelvic wall(s) * Rectum, NOS, excluding mucosa * Rectal wall * Urethra D
600 Infiltration of abdominal tissues (code 550), more than one site FIGO Stage IIIB D
650 Abdominal tissues involvement, NOS FIGO Stage III [NOS] D
700 Bladder wall Bladder, NOS excluding mucosa Rectal wall Rectum, NOS excluding mucosa RE
750 Bladder mucosa (for bullous edema of bladder mucosa, see code 550) Rectal mucosa Sigmoid colon Small intestine FIGO Stage IVA Further contiguous extension D
800 No evidence of primary tumor U
999 Unknown; extension not stated Primary tumor cannot be assessed Not documented in medical record Death Certificate Only U
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998 (2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001. (3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL) (4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017 (5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017 (6) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017